The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is responsible of variable clinical manifestations, ranging from no symptoms to severe pneumonia with acute respiratory distress syndrome, septic shock, and multi-organ failure resulting in death. To date no specific antiviral dr...
Main Authors: | Lucia Gozzo, Pierluigi Viale, Laura Longo, Daniela Cristina Vitale, Filippo Drago |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.01307/full |
Similar Items
-
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial
by: Michelle Sholzberg, et al.
Published: (2021-03-01) -
Preventing Thrombohemorrhagic Complications of Heparinized COVID-19 Patients Using Adjunctive Thromboelastography: A Retrospective Study
by: Connor M. Bunch, et al.
Published: (2021-07-01) -
The Coagulopathy Bleeding in Disseminated Intravascular Coagulation. Therapy by Heparin and Treatment Plasmapheresis
by: Kurgan M., et al.
Published: (2015-12-01) -
Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
by: Baranca Buijsers, et al.
Published: (2020-09-01) -
Coagulopathy in COVID-19
by: Ka U Lio, et al.
Published: (2021-01-01)